AbbVie reported a robust Q1 2026 with net revenue up 12.4% year-over-year, fueled by strong sales in Immunology drugs Skyrizi (+29%) and Rinvoq (+20%), as well as a 24% increase in Neuroscience products. The company raised its 2026 earnings per share guidance to $14.18, indicating a 42% growth from the previous year. With a solid pipeline, diversified growth drivers, a 3.4% dividend yield, and a strong balance sheet, AbbVie is rated a 'Buy' for investors seeking both income and growth. This outlook reflects confidence in AbbVie's ability to sustain momentum and deliver shareholder value.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
The Vanguard Short-Term Corporate Bond Index ETF (VCSH) yields about 4.42%, significantly higher than typical 1-year CDs which offer around 1.5%-2.0%, with top CDs reaching 4.0%. While CDs provide FDIC insurance and guaranteed income, VCSH carries ri...
Realty Income's high valuation and rising debt raise concerns despite its long streak of dividend increases. Its earnings are declining, interest expenses are rising, and growth projections are modest. In contrast, AbbVie shows strong dividend growth...
